Salarius Pharmaceuticals Inc.
08/18/2025 | Press release | Distributed by Public on 08/18/2025 06:34
Management Change/Compensation (Form 8-K)
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 17, 2025, the Board of Directors (the "Board") of Salarius Pharmaceuticals, Inc. (the "Company") appointed Mark J. Rosenblum as the acting Chief Executive Officer of the Company and designated him as the Company's "principal executive officer" (the "Acting CEO Appointment"). Mr. Rosenblum will also continue serving in his role as Executive Vice President and Chief Financial Officer of the Company.
The Acting CEO Appointment was made in connection with the resignation of David J. Arthur as Chief Executive Officer of the Company on August 17, 2025. Mr. Arthur's resignation is not a result of any disagreement with the Company. Mr. Arthur continues to serve as a member of the Board and support the Company as it works to finalize its previously announced merger transaction with Decoy Therapeutics Inc. In connection with Mr. Arthur's resignation, the Company terminated that certain Consulting Agreement, dated February 20, 2024, as amended, by and between the Company and Mr. Arthur, effective immediately.
Mr. Rosenblum, 72, has served as the Company's Executive Vice President Finance and Chief Financial Officer since September 2019. Prior to September 2019, Mr. Rosenblum served as a financial consultant to the Company since February 2019. Prior to joining the Company, Mr. Rosenblum served as chairman, chief executive officer and a director of ActiveCare, Inc. (Nasdaq: ACAR), a healthcare company, from December 2017 to March 2019, which was sold to Biotelemetry, Inc (now Royal Philips (NYSE: PHG). Mr. Rosenblum worked as a financial consultant for various companies from 2014 to 2017. Prior to that, Mr. Rosenblum served as the chief financial officer of Advaxis, Inc. (Nasdaq: ADXS), a biotechnology company, from January 2010 to April 2014. From 1985 through 2003, Mr. Rosenblum was employed by Wellman, Inc., a global public chemical manufacturer, which was subsequently acquired by DAK Americas, serving in various capacities including chief accounting officer. Mr. Rosenblum holds both a Masters in Accountancy and a B.S. degree in Accounting from the University of South Carolina. Mr. Rosenblum began his career in 1977 with Haskins & Sells, CPA (currently known as Deloitte), was a licensed Certified Public Accountant for over 30 years, and is currently a member of the American Institute of Certified Public Accountants.
The Company did not enter into any new consulting or employment agreement with Mr. Rosenblum in connection with the PEO Appointment and the existing employment agreement between the Company and Mr. Rosenblum remains in effect. There is no arrangement or understanding between Mr. Rosenblum and any other person pursuant to which Mr. Rosenblum was appointed as acting CEO of the Company, and there is no family relationship between Mr. Rosenblum and any of the Company's directors or other executive officers. There are no related party transactions between Mr. Rosenblum and the Company that would require disclosure under Item 404(a) of Regulation S-K.
Salarius Pharmaceuticals Inc. published this content on August 18, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on August 18, 2025 at 12:34 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]